518044-31-0 Usage
Description
Hydroxy-PEG3-t-butyl acetate, also known as Hydroxy-PEG3-CH2CO2tBu, is a PEG (polyethylene glycol) linker that features a hydroxyl group with a t-butyl protected carboxyl group. This molecule is characterized by its hydrophilic PEG spacer, which enhances solubility in aqueous media, and the hydroxyl group that allows for further derivatization or substitution with other reactive functional groups. The t-butyl protected carboxyl group can be deprotected under acidic conditions, making it a versatile compound for various applications.
Uses
Used in Pharmaceutical Industry:
Hydroxy-PEG3-t-butyl acetate is used as a molecular building block for the development of drug conjugates and prodrugs. The hydrophilic PEG spacer improves the solubility and pharmacokinetic properties of the resulting drug molecules, while the hydroxyl and t-butyl protected carboxyl groups facilitate chemical modifications and conjugation to therapeutic agents.
Used in Bioconjugation and Chemical Synthesis:
Hydroxy-PEG3-t-butyl acetate serves as a versatile intermediate for the synthesis of bioconjugates, such as PEGylated proteins, peptides, and other biomolecules. The hydroxyl group allows for the attachment of various functional groups, while the t-butyl protected carboxyl group can be deprotected under acidic conditions to enable further reactions.
Used in Drug Delivery Systems:
In the field of drug delivery, Hydroxy-PEG3-t-butyl acetate is used as a component in the design of targeted drug delivery systems. The PEG spacer can be utilized to improve the solubility and circulation time of drug-loaded nanoparticles or liposomes, while the functional groups enable the attachment of targeting ligands or other therapeutic agents.
Used in Diagnostics and Imaging:
Hydroxy-PEG3-t-butyl acetate can be employed in the development of contrast agents for medical imaging techniques, such as magnetic resonance imaging (MRI) or computed tomography (CT). The hydrophilic PEG spacer and functional groups can be used to enhance the stability and biocompatibility of imaging agents, while the t-butyl protected carboxyl group allows for the incorporation of imaging moieties.
Used in Cosmetics and Personal Care:
In the cosmetics and personal care industry, Hydroxy-PEG3-t-butyl acetate is used as an ingredient in the formulation of skin care and hair care products. The hydrophilic PEG spacer improves the solubility and skin permeation of active ingredients, while the hydroxyl and t-butyl protected carboxyl groups enable the creation of stable emulsions and gels.
Check Digit Verification of cas no
The CAS Registry Mumber 518044-31-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,1,8,0,4 and 4 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 518044-31:
(8*5)+(7*1)+(6*8)+(5*0)+(4*4)+(3*4)+(2*3)+(1*1)=130
130 % 10 = 0
So 518044-31-0 is a valid CAS Registry Number.
518044-31-0Relevant articles and documents
Heterocyclic compound and application thereof
-
Paragraph 1345-1347; 1350, (2021/08/07)
The invention discloses a heterocyclic compound and application thereof. The invention provides a heterocyclic compound as shown in a formula I, or pharmaceutically acceptable salt thereof. The heterocyclic compound can be used for degrading ALK, c-Met and ROS proteins.
Di-substituted maleic amide linker for antibody drug conjugating and preparation method and use thereof
-
Page/Page column 132; 133, (2021/04/28)
Provided in the present invention are a di-substituted maleic amide linker conjugated to an antibody and a preparation method and use thereof. In particular, the present invention conjugates a strongly cytotoxic active substance to a biomacromolecule thro
Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma
Tu, Yalin,Sun, Yameng,Qiao, Shuang,Luo, Yao,Liu, Panpan,Jiang, Zhong-Xing,Hu, Yumin,Wang, Zifeng,Huang, Peng,Wen, Shijun
, p. 10167 - 10184 (2021/07/26)
Traditional EZH2 inhibitors are developed to suppress the enzymatic methylation activity, and they may have therapeutic limitations due to the nonenzymatic functions of EZH2 in cancer development. Here, we report proteolysis-target chimera (PROTAC)-based EZH2 degraders to target the whole EZH2 in lymphoma. Two series of EZH2 degraders were designed and synthesized to hijack E3 ligase systems containing either von Hippel-Lindau (VHL) or cereblon (CRBN), and some VHL-based compounds were able to mediate EZH2 degradation. Two best degraders, YM181 and YM281, induced robust cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphomas, outperforming a clinically used EZH2 inhibitor EPZ6438 (tazemetostat) that was only effective against DLBCL. The EZH2 degraders displayed promising antitumor activities in lymphoma xenografts and patient-derived primary lymphoma cells. Our study demonstrates that EZH2 degraders have better therapeutic activity than EZH2 inhibitors, which may provide a potential anticancer strategy to treat lymphoma.
